| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ODN D-SL-01 targets Toll-like receptor 9 (TLR9), a pattern recognition receptor that is part of the innate immune system. TLR9 recognizes unmethylated CpG motifs, which are common in bacterial and viral DNA. As a CpG ODN, ODN D-SL-01 mimics this pathogen-associated molecular pattern, binding to TLR9 and triggering a signaling cascade that leads to the activation of immune cells, including dendritic cells and B cells, and the production of pro-inflammatory cytokines.
|
|---|---|
| ln Vitro |
In vitro, ODN D-SL-01 demonstrates potent immunostimulatory activity. It activates immune cells by binding to TLR9, leading to the production of various cytokines and chemokines. This activity has been observed in a variety of vertebrate species. The compound's specific EC50 values are not provided in the available sources, but its activity is well-characterized in functional assays measuring immune cell activation.
|
| ln Vivo |
In vivo, ODN D-SL-01 has shown anticancer activity. As a TLR9 agonist, it can activate the immune system to mount an anti-tumor response. It is being studied for its potential as an immunotherapeutic agent. Specific in vivo efficacy data, such as effects on tumor growth in animal models, are not detailed in the available sources.
|
| Enzyme Assay |
A cell-free assay for ODN D-SL-01 is not applicable as it is an oligonucleotide that acts by binding to a cell surface receptor. Its activity is assessed in cell-based functional assays. The compound's purity and sequence are confirmed by standard analytical techniques such as mass spectrometry and HPLC.
|
| Cell Assay |
Cellular assays for ODN D-SL-01 typically involve measuring its ability to activate TLR9-expressing immune cells, such as peripheral blood mononuclear cells (PBMCs) or plasmacytoid dendritic cells. Cells are treated with the ODN, and the production of cytokines like IFN-α, IL-6, and TNF-α is measured. The upregulation of activation markers on the cell surface can also be assessed by flow cytometry.
|
| Animal Protocol |
In vivo animal experiments for ODN D-SL-01 would typically involve its administration to tumor-bearing mice to evaluate its anti-tumor efficacy. The compound's ability to activate the immune system and inhibit tumor growth would be assessed. Specific protocols are not detailed in the available sources.
|
| ADME/Pharmacokinetics |
ODN D-SL-01 is an oligonucleotide and does not have conventional small-molecule pharmacokinetic properties. It is typically administered as a solution. Specific stability and storage conditions are not detailed in the available sources. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Toxicity data for ODN D-SL-01 are not provided in the available sources. As an immunostimulatory agent, it may have the potential to induce inflammatory responses. It is intended for research use only and is not for human consumption.
|
| References | |
| Additional Infomation |
ODN D-SL-01 (CAS: 1198621-84-9) is a class B CpG ODN and TLR9 agonist. Its sequence is 5'-TCGCGACGTTCGCCCGACGTTCGGTA-3'. It is used in research to study innate immunity and as a potential immunotherapeutic agent for cancer. It is not an approved drug and is strictly for research purposes.
|
| Molecular Formula |
NAMOLECULARWEIGHT
|
|---|---|
| Molecular Weight |
0
|
| CAS # |
1198621-84-9
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~20 mg/mL (~2.40 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
